# A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

> **NCT03267316** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cantargia AB** · enrollment: 167 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Pancreatic Ductal Adenocarcinoma
- Triple Negative Breast Cancer
- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** CAN04
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT03267316
- **Lead sponsor:** Cantargia AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-19
- **Primary completion:** 2024-03-14
- **Final completion:** 2024-03-14
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03267316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03267316, "A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03267316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*